欢迎来到天天文库
浏览记录
ID:70790481
大小:22.55 KB
页数:10页
时间:2021-11-24
《伊立替康联合卡铂治疗晚期非小细胞肺癌的临床效果观察x》由会员上传分享,免费在线阅读,更多相关内容在行业资料-天天文库。
1、伊立替康联合卡铂治疗晚期非小细胞肺癌的临床效果观察【摘要】目的观察伊立替康(CPT-11)联合卡铂(CBP)方案(IC)治疗晚期非小细胞肺癌(NSCLC)的疗效及不良反应。方法46例经病理学或细胞学确诊的晚期NSCLC患者,接受CPT-1150mg/m2,d1、8静脉滴注;卡铂按Chatelut公式AUC=5,d1静脉滴注,21d为1个周期。至少化疗2个周期后评价客观反应率、疾病控制、无进展生存、总生存及不良反应。结果全组部分缓解(PR)16例,病情稳定(SD)12例,疾病进展(PD)18例,有效率(RR)34
2、.8%,疾病控制率(DCR)60.9%,中位无进展生存时间(PFS)5.8个月,中位总生存时间(OS)11.6个月,主要不良反应为3~4级粒细胞减少、血小板减少、恶心呕吐、迟发型腹泻、脱发。结论CPT-11联合CBP治疗NSCLC疗效确切,患者对不良反应耐受性较好。【关键词】晚期非小细胞肺癌;伊立替康;卡铂DOI:10.14163/ki.11-5547/r.2016.04.001Observationofclinicaleffectbyirinotecancombinedwithcarboplatininthe
3、treatmentofadvancednon-smallcelllungcancerZHANGJian,SHAOLi-hua.DepartmentofMedicalOncology,LiaoningDandongCityHospitalofTraditionalChineseMedicine,Dandong118000,China【Abstract】ObjectiveToobservecurativeeffectand第10页共10页adversereactionsbyirinotecan(CPT-11)com
4、binedwithcarboplatin(CBP)solution(IC)inthetreatmentofadvancednon-smallcelllungcancer(NSCLC).MethodsAtotalof46patientswithpathologicallyorcytologicallydiagnosedadvancedNSCLCreceivedCPT-1150mg/m2,d1、8throughintravenousdripandcarboplatinbyChatelutformulaAUC=5,d
5、1throughintravenousdrip.Thetreatmentlastedfor21das1course.After2coursesofchemotherapy,objectiveresponserate,diseasecontrolrate,progression-freesurvival,totalsurvivalandadversereactionswereevaluated.ResultsTherewere16partialremission(PR)cases,12stabledisease(
6、SD)casesand18progressivedisease(PD)cases.Reaponseratewas34.8%,diseasecontrolrate(DCR)was60.9%,medianprogression-freesurvival(PFS)timewas5.8months,andmedianoverallsurvival(OS)timewas11.6months.Mainadversereactionsincludedgrade3~4granulocytopenia,thrombocytope
7、nia,nausea,emesis,diarrhea,andalopecia.ConclusionCombinationofCPT-11andCBPprovidespreciseeffectintreatingNSCLC,withgoodtoleranceofadversereactionsinpatients.【Keywords】Advancednon-smallcelllungcancer;Irinotecan;Carboplatin第10页共10页肺癌是我国发病率及死亡率居首位的
此文档下载收益归作者所有